Bioequivalence and Bioavailability Forum 02:04 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

rajasekharkakarla
Junior

India,
2018-05-03 12:28

Posting: # 18753
Views: 680
 

 Steady State design [Design Issues]

Dear Sir/Madam,

I have some doubts in designing study state protocols.

Example: Tamsulosin

how to fix number of days to dosing

how to fix number of doses per day

My regular practice is if label/smpc states achievement of steady-state concentrations by the fifth day of once-a-day dosing for Tamsulosin, i will design the study state protocol with once a day dosing for five days. but i want to know the exact scientific rationale behind this.

please help me...

Regards,
Rajasekhar


Edit: Category changed; see also this post #1. [Helmut]
Helmut
Hero
avatar
Homepage
Vienna, Austria,
2018-05-03 14:12

@ rajasekharkakarla
Posting: # 18754
Views: 562
 

 5–7 predominant half lives

Hi Rajasekhar,

» Example: Tamsulosin
» how to fix number of days to dosing

Until (pseudo) steady state is achieved. See this post for an example of linear PK.
Which regulation are you “targeting”? For the FDA a multiple dose study is not required. Since the SmPC recommends intake after breakfast, according to the EMA’s GL the multiple dose study has to be performed in fed state.

» how to fix number of doses per day

According to the posology of the reference (for tamsulosin OAD after breakfast).

» My regular practice is if label/smpc states achievement of steady-state concentrations by the fifth day of once-a-day dosing for Tamsulosin, i will design the study state protocol with once a day dosing for five days.

Fine but copy/paste ≠ science. :-D

» […] i want to know the exact scientific rationale behind this.

Kudos. Steady state is practically reached after 5–7 predominant half lives (96.9–99.2% of theoretical steady state). Note that Flomax® is a CR-formulation (flip-flop PK, where ka < ke). Whereas the elimination half life (after IV or IR) is ~6–7 hours, the apparent one of the CR is substantially prolonged (see the FDA’s NDA approval; page 217 of the PDF).

For drugs with nonlinear PK (e.g., saturation of metabolizing enzymes, auto-induction or -inhibition) it is complicated. Consult with a pharmacokineticist.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,697 posts in 3,982 threads, 1,232 registered users;
online 15 (0 registered, 15 guests [including 11 identified bots]).

I have had my results for a long time:
but I do not yet know how I am to arrive
at them.    Carl Friedrich Gauß

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed